Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the ...
The results of the study, dubbed MAPP2, will support the submission of a newdrug approval application expected from MAPS PBC in the third quarter of 2023. “The Phase 3 confirmatory results ...